P1–313: Reproducibility of intracranial and hippocampal volume quantification at 1.5T and 3T MRI: Application to ADNI I

Roche, Florent; Singh, Baljeet; Schaerer, Joël; Belaroussi, Boubakeur; Gouttard, Sylvain; Istace, Audrey; Yu, Hui Jing; Fletcher, Evan; Bracoud, Luc; Pachaï, Chahin; DeCarli, Charles

doi:10.1016/j.jalz.2013.05.539

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies found that while most of the brain was identically classified at the two field strengths, there were some regional differences observed (West et al., 2013). Others have reported highly reproducible volumetric data in adults with AD and controls, scanned on 1.5T and 3T scanners (Roche et al., 2013). Upon closer investigation when comparing DS fetal datasets acquired on 1.5T ( n = 12) and 3T ( n = 18) scanners, we were able to conclude that there were no discernible differences in volumetric data.…”

Section: Discussionmentioning

confidence: 99%

Early alterations in cortical and cerebellar regional brain growth in Down Syndrome: An in vivo fetal and neonatal MRI assessment

Patkee

Baburamani

Kyriakopoulou

et al. 2020

NeuroImage: Clinical

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Early alterations in cortical and cerebellar regional brain growth in Down Syndrome: An in vivo fetal and neonatal MRI assessment

Patkee

Baburamani

Kyriakopoulou

et al. 2020

NeuroImage: Clinical

View full text Add to dashboard Cite

show abstract

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014

Weiner

Veitch

Aisen

et al. 2015

Alzheimer's & Dementia

214

166

View full text Add to dashboard Cite

Introduction The Alzheimer’s Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer’s disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using established methods. Results ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson’s disease and multiple sclerosis. Discussion ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.

show abstract

Early alterations in cortical and cerebellar regional brain growth in Down Syndrome: An in-vivo fetal and neonatal MRI assessment

Patkee

Baburamani

Kyriakopoulou

et al. 2019

Preprint

View full text Add to dashboard Cite

Down Syndrome (DS) is the most frequent genetic cause of intellectual disability with a wide spectrum of neurodevelopmental outcomes. At present, the relationship between structural brain morphology and the spectrum of cognitive phenotypes in DS, is not well understood. This study aimed to quantify development of the fetal and neonatal brain in DS using dedicated, optimised and motion-corrected invivo magnetic resonance imaging (MRI). We detected deviations in development and altered regional brain growth in the fetus with DS from 21 weeks' gestation, when compared to age-matched controls.Reduced cerebellar volume was apparent in the second trimester with significant alteration in cortical growth becoming evident during the third trimester. Developmental abnormalities in the cortex and cerebellum are likely substrates for later neurocognitive impairment, and ongoing studies will allow us to confirm the role of antenatal MRI as an early biomarker for subsequent cognitive ability in DS. In the era of rapidly developing technologies, it is hoped that the results of this study will assist counselling for prospective parents.

show abstract

P1–313: Reproducibility of intracranial and hippocampal volume quantification at 1.5T and 3T MRI: Application to ADNI I

Cited by 3 publications

References 0 publications

Early alterations in cortical and cerebellar regional brain growth in Down Syndrome: An in vivo fetal and neonatal MRI assessment

Early alterations in cortical and cerebellar regional brain growth in Down Syndrome: An in vivo fetal and neonatal MRI assessment

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014

Early alterations in cortical and cerebellar regional brain growth in Down Syndrome: An in-vivo fetal and neonatal MRI assessment

Contact Info

Product

Resources

About